Onkoloji Araştırmaları Derneği
Bilimsel Kuruluş
2017
Başkan Yardımcısı
Profesör
İstinye Üniversitesi
Tıp Fakültesi
İç Hastalıkları Anabilim Dalı
Bilimsel Kuruluş
Bilimsel Kuruluş
Bilimsel Kuruluş
Bilimsel Kuruluş
Bilimsel Kuruluş
Bilimsel Kuruluş
Editör
Yrd. Editör
Editör
Editör
Yrd. Editör
Editör
Editör
Yayın Kurulu Üyeliği
Yayın Kurulu Üyeliği
Dergi
Dergi
Dergi
Dergi
Dergi
Dergi
Dergi
Dergi
Kurs
Araştırmacının Sorumlulukları (eğitici)
Çalıştay
Türkiye'de Klinik çalışmalara dair rapor ve önerilerin oluşturulması
Sertifika
Klnik çalışmalara dair
Araştırma
We conducted a randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation and human epidermal growth factor receptor type 2 (HER2)–negative metastatic breast cancer who had received no more than two previous chemotherapy regimens for metastatic disease. Patients were randomly assigned, in a 2:1 ratio, to receive olaparib tablets (300 mg twice daily) or standard therapy with single-agent chemotherapy of the physician’s choice (capecitabine, eribulin, or vinorelbine in 21-day cycles). The primary end point was progression-free survival, which was assessed by blinded independent central review and was analyzed on an intention-to-treat basis.
Araştırma
Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive non–small-cell lung cancer (NSCLC). We investigated alectinib as compared with crizotinib in patients with previously untreated, advanced ALK-positive NSCLC, including those with asymptomatic CNS disease
Yönetim Kurulu Üyesi
İçhastalıkları ve Tıbbi Onkoloji uzmanı
Tıbbi Onkoloji Uzmanı
İç Hastalıkları Uzmanı
Kaynak: YÖK Akademik